Navigation Links
Amgen Announces Voting Results Of Annual Meeting of Stockholders
Date:5/20/2011

anies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

Forward Looking Statements

This release contains forward-looking statements that are based on management's current expectations and beliefs.  All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements regarding: Amgen's intention to initiate a quarterly common stock dividend; the planned repurchase of our common stock; the planned return of capital to stockholders; expected payout ratios; the anticipated revenues of our products, including Prolia and XGEVA; our business strategy and future capital position; estimates of dividend distributions, stock repurchases, revenues, operating margins, capital expenditures, cash or other financial metrics in any current or future period; expected legal, arbitration, political, regulatory or clinical results or practices; customer and prescriber patterns or practices; reimbursement activities and outcomes; and other such estimates and results.  Forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those described, including those risks discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and subsequent reports on Form 10-Q and Form 8-K.&
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
2. Amgen Oncology Data to be Presented at ASCO Annual Meeting
3. Amgen to Webcast Investor Meeting at Upcoming American Urological Association Conference
4. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
5. Amgen to Present at the Deutsche Bank 36th Annual Healthcare Conference
6. Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
7. Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)
8. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
9. Amgen to Webcast 2011 Business Review Meeting on April 21
10. Amgen Announces Webcast of 2011 First Quarter Financial Results
11. Amgen Establishes Commercial Operations in Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... 2010 Genomic Health, Inc. (Nasdaq: GHDX ) today ... 30, 2010. Total revenue increased to $46.3 million in ... third quarter of 2009.  Product revenue was $45.8 million in the ... $38.9 million in the third quarter of 2009. ...
... Nov. 8, 2010 PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly dividend of $.12 per share ...  The dividend will be payable December 15, 2010, to shareholders ... public in 1984 Mesa Labs has maintained strong cash positions ...
Cached Medicine Technology:Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 8
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... serve as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who ... help the college expand its reach and impact through innovative technologies and strategies. , ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... one of two inventors from Miller Place, N.Y. "I specialize in manual therapy, ... discomfort. In addition, it can be used for additional muscle dysfunction throughout the ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma injections ... have shown through research to improve treatment outcomes. This localized treatment seems ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a growing number ... recently transitioned management companies to partner with Wound Care Advantage (WCA) to utilize ... center. , Transitioning wound care management providers can be a complex undertaking. ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... Texas Mutual Insurance Company, an,aggressive tort reform advocate ... pending litigation in which the insurance company tried,to overturn ... for a workplace injury,a Dallas state district judge ruled ... falsified medical record,Texas Mutual had no evidence to continue ...
... CHICAGO, Jan. 9 To make your New ... Pretzels(R) (K&SGP) introduces its,Empowered Pretzel(TM), the first of ... healthful twist on the traditional pretzel. The,pretzel is ... http://www.kimandscotts.com or by calling the company at ...
... Health Care,Associates, Inc. (MHA), the nation,s largest alternate ... members, Mr. Barry R. Freedman and,Mr. Brian Wheelan ... and Mr.,Wheelan join seven existing board members representing ... Barry Freedman is President and Chief Executive Officer ...
... GSI Group Inc.,(Nasdaq: GSIG ), a leading ... it will be presenting at both the,Needham & Company ... January,10th and the Fifth Annual Sidoti & Company Emerging ... Mr. Robert Bowen, Chief Financial Officer, will be speaking ...
... Jan. 9 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX -,News) stated ... of,AlphaRx Inc Common Stock in the open market, bringing ... last 60 days, reflecting his,continued confidence in the Company,s ... of 720,000 AlphaRx shares for,an average price of $0.24 ...
... 2008 Meeting of the American Psychoanalytic Association, psychoanalysts Susan ... Ph.D. (Boston, MA) will lead a discussion regarding "Psychoanalytic ... Dialogue between Psychoanalysis and Neurobiology." This session will be ... 10: 00 pm at the Waldorf-Astoria Hotel, 301 Park ...
Cached Medicine News:Health News:Judge Rules Texas Mutual Insurance Co. Committed Litigation Fraud With Falsified Document, According to Doyle Raizner LLP 2Health News:Kim & Scott's Gourmet Pretzels(R) Introduces Its First Empowered Pretzel(TM) Available Online and to Wholesale 2Health News:MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors 2Health News:MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors 3Health News:GSI to Present at Upcoming Investor Growth Conferences 2
... revised charts incorporate the slight change in ... 10 Sloan letters derived from the best ... during the ETDRS study. The original charts ... of 234 eyes. In addition to the ...
... The Stereo Tower is used to ... and adults without the use of ... tests can be used for study, testing ... form and depth perception. The instruction card ...
... to simplify stereopsis screening in children. It is ... gratings. Lang Stereotest II measures disparities: Moon and ... seconds of arc plus monocularly visible star. In ... are smaller and less dense. This disparity is ...
... This "natural" Stereotest consists of three test plates(6mm, ... measurements in a range of 600 - 15 ... shape can only be detected if stereopsis is ... the risk of the patient learning the correct ...
Medicine Products: